783 reports of this reaction
8.1% of all RAMUCIRUMAB reports
#1 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #1 most commonly reported adverse reaction for RAMUCIRUMAB, manufactured by Eli Lilly and Company. There are 783 FDA adverse event reports linking RAMUCIRUMAB to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 8.1% of all 9,650 adverse event reports for this drug.
Patients taking RAMUCIRUMAB who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is moderately reported among RAMUCIRUMAB users, representing a notable but not dominant share of adverse events.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for RAMUCIRUMAB:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 783 FDA reports for RAMUCIRUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 8.1% of all adverse event reports for RAMUCIRUMAB, making it one of the most commonly reported side effect.
If you experience malignant neoplasm progression while taking RAMUCIRUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.